David S Hong1, Marwan G Fakih1, John H Strickler1, Jayesh Desai1, Gregory A Durm1, Geoffrey I Shapiro1, Gerald S Falchook1, Timothy J Price1, Adrian Sacher1, Crystal S Denlinger1, Yung-Jue Bang1, Grace K Dy1, John C Krauss1, Yasutoshi Kuboki1, James C Kuo1, Andrew L Coveler1, Keunchil Park1, Tae Won Kim1, Fabrice Barlesi1, Pamela N Munster1, Suresh S Ramalingam1, Timothy F Burns1, Funda Meric-Bernstam1, Haby Henary1, Jude Ngang1, Gataree Ngarmchamnanrith1, June Kim1, Brett E Houk1, Jude Canon1, J Russell Lipford1, Gregory Friberg1, Piro Lito1, Ramaswamy Govindan1, Bob T Li1. 1. From the Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, University of Texas M.D. Anderson Cancer Center, Houston (D.S.H., F.M.-B.); the Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte (M.G.F.), the University of California, San Francisco, San Francisco (P.N.M.), and Amgen, Thousand Oaks (H.H., J.N., G.N., J.K., B.E.H., J.C., J.R.L., G.F.) - all in California; Duke University Medical Center, Durham, NC (J.H.S.); Royal Melbourne Hospital/Peter MacCallum Cancer Centre, Melbourne, VIC (J.D.), Queen Elizabeth Hospital and University of Adelaide, Woodville South, SA (T.J.P.), and Scientia Clinical Research, Randwick, NSW (J.C. Kuo) - all in Australia; the Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis (G.A.D.); Dana-Farber Cancer Institute, Harvard Medical School, Boston (G.I.S.); the Sarah Cannon Research Institute at HealthONE, Denver (G.S.F.); Princess Margaret Cancer Centre, University Health Network, Toronto (A.S.); Fox Chase Cancer Center, Philadelphia (C.S.D.); the University of Pittsburgh Medical Center Hillman Cancer Center, University of Pittsburgh, Pittsburgh (T.F.B.); Seoul National University College of Medicine (Y.-J.B.), Samsung Medical Center, Sungkyunkwan University School of Medicine (K.P.), and the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (T.W.K.) - all in Seoul, South Korea; Roswell Park Cancer Institute, Buffalo (G.K.D.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York (P.L., B.T.L.) - all in New York; the University of Michigan, Ann Arbor (J.C. Krauss); the Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan (Y.K.); the Department of Medicine, Division of Oncology, University of Washington, Seattle (A.L.C.); Aix Marseille University, Centre National de la Recherche Scientifique, INSERM, Centre de Recherche en Cancérologie de Marseille, Assistance Publique-Hôpitaux de Marseille, Marseille, France (F.B.); Winship Cancer Institute of Emory University, Atlanta (S.S.R.); and the Alvin J. Siteman Cancer Center at Washington University School of Medicine, St. Louis (R.G.).
Abstract
BACKGROUND: No therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non-small-cell lung cancers (NSCLCs) and in 1 to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C. METHODS: We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G12C mutation. Patients received sotorasib orally once daily. The primary end point was safety. Key secondary end points were pharmacokinetics and objective response, as assessed according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. RESULTS: A total of 129 patients (59 with NSCLC, 42 with colorectal cancer, and 28 with other tumors) were included in dose escalation and expansion cohorts. Patients had received a median of 3 (range, 0 to 11) previous lines of anticancer therapies for metastatic disease. No dose-limiting toxic effects or treatment-related deaths were observed. A total of 73 patients (56.6%) had treatment-related adverse events; 15 patients (11.6%) had grade 3 or 4 events. In the subgroup with NSCLC, 32.2% (19 patients) had a confirmed objective response (complete or partial response) and 88.1% (52 patients) had disease control (objective response or stable disease); the median progression-free survival was 6.3 months (range, 0.0+ to 14.9 [with + indicating that the value includes patient data that were censored at data cutoff]). In the subgroup with colorectal cancer, 7.1% (3 patients) had a confirmed response, and 73.8% (31 patients) had disease control; the median progression-free survival was 4.0 months (range, 0.0+ to 11.1+). Responses were also observed in patients with pancreatic, endometrial, and appendiceal cancers and melanoma. CONCLUSIONS: Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation. Grade 3 or 4 treatment-related toxic effects occurred in 11.6% of the patients. (Funded by Amgen and others; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).
BACKGROUND: No therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non-small-cell lung cancers (NSCLCs) and in 1 to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C. METHODS: We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G12C mutation. Patients received sotorasib orally once daily. The primary end point was safety. Key secondary end points were pharmacokinetics and objective response, as assessed according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. RESULTS: A total of 129 patients (59 with NSCLC, 42 with colorectal cancer, and 28 with other tumors) were included in dose escalation and expansion cohorts. Patients had received a median of 3 (range, 0 to 11) previous lines of anticancer therapies for metastatic disease. No dose-limiting toxic effects or treatment-related deaths were observed. A total of 73 patients (56.6%) had treatment-related adverse events; 15 patients (11.6%) had grade 3 or 4 events. In the subgroup with NSCLC, 32.2% (19 patients) had a confirmed objective response (complete or partial response) and 88.1% (52 patients) had disease control (objective response or stable disease); the median progression-free survival was 6.3 months (range, 0.0+ to 14.9 [with + indicating that the value includes patient data that were censored at data cutoff]). In the subgroup with colorectal cancer, 7.1% (3 patients) had a confirmed response, and 73.8% (31 patients) had disease control; the median progression-free survival was 4.0 months (range, 0.0+ to 11.1+). Responses were also observed in patients with pancreatic, endometrial, and appendiceal cancers and melanoma. CONCLUSIONS: Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation. Grade 3 or 4 treatment-related toxic effects occurred in 11.6% of the patients. (Funded by Amgen and others; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).
Authors: Matthew P Patricelli; Matthew R Janes; Lian-Sheng Li; Rasmus Hansen; Ulf Peters; Linda V Kessler; Yuching Chen; Jeff M Kucharski; Jun Feng; Tess Ely; Jeffrey H Chen; Sarah J Firdaus; Anjali Babbar; Pingda Ren; Yi Liu Journal: Cancer Discov Date: 2016-01-06 Impact factor: 39.397
Authors: Ondrej Fiala; Tomas Buchler; Beatrice Mohelnikova-Duchonova; Bohuslav Melichar; Vit Martin Matejka; Lubos Holubec; Jana Kulhankova; Zbynek Bortlicek; Marie Bartouskova; Vaclav Liska; Ondrej Topolcan; Monika Sedivcova; Jindrich Finek Journal: Tumour Biol Date: 2015-12-10
Authors: Ken Suzawa; Michael Offin; Daniel Lu; Christopher Kurzatkowski; Morana Vojnic; Roger S Smith; Joshua K Sabari; Huichun Tai; Marissa Mattar; Inna Khodos; Elisa de Stanchina; Charles M Rudin; Mark G Kris; Maria E Arcila; William W Lockwood; Alexander Drilon; Marc Ladanyi; Romel Somwar Journal: Clin Cancer Res Date: 2018-10-23 Impact factor: 12.531
Authors: Erminia Massarelli; Marileila Varella-Garcia; Ximing Tang; Ana C Xavier; Natalie C Ozburn; Diane D Liu; Benjamin N Bekele; Roy S Herbst; Ignacio I Wistuba Journal: Clin Cancer Res Date: 2007-05-15 Impact factor: 12.531
Authors: Eric Van Cutsem; Sanne Huijberts; Axel Grothey; Rona Yaeger; Pieter-Jan Cuyle; Elena Elez; Marwan Fakih; Clara Montagut; Marc Peeters; Takayuki Yoshino; Harpreet Wasan; Jayesh Desai; Fortunato Ciardiello; Ashwin Gollerkeri; Janna Christy-Bittel; Kati Maharry; Victor Sandor; Jan H M Schellens; Scott Kopetz; Josep Tabernero Journal: J Clin Oncol Date: 2019-03-20 Impact factor: 44.544
Authors: Jason T Henry; Oluwadara Coker; Saikat Chowdhury; John Paul Shen; Van K Morris; Arvind Dasari; Kanwal Raghav; Maliha Nusrat; Bryan Kee; Christine Parseghian; Shubham Pant; Nikeshan Jeyakumar; Limin Zhu; Yujiro Nishioka; David Fogelman; Robert A Wolff; David Hong; Michael J Overman; JeanNicolas Vauthey; Scott Kopetz; Benny Johnson Journal: JCO Precis Oncol Date: 2021-04-06
Authors: Mark M Awad; Shengwu Liu; Igor I Rybkin; Kathryn C Arbour; Julien Dilly; Viola W Zhu; Melissa L Johnson; Rebecca S Heist; Tejas Patil; Gregory J Riely; Joseph O Jacobson; Xiaoping Yang; Nicole S Persky; David E Root; Kristen E Lowder; Hanrong Feng; Shannon S Zhang; Kevin M Haigis; Yin P Hung; Lynette M Sholl; Brian M Wolpin; Julie Wiese; Jason Christiansen; Jessica Lee; Alexa B Schrock; Lee P Lim; Kavita Garg; Mark Li; Lars D Engstrom; Laura Waters; J David Lawson; Peter Olson; Piro Lito; Sai-Hong I Ou; James G Christensen; Pasi A Jänne; Andrew J Aguirre Journal: N Engl J Med Date: 2021-06-24 Impact factor: 91.245
Authors: Paul Yenerall; Rahul K Kollipara; Kimberley Avila; Michael Peyton; Christopher A Eide; Daniel Bottomly; Shannon K McWeeney; Yan Liu; Kenneth D Westover; Brian J Druker; John D Minna; Ralf Kittler Journal: Cancer Res Date: 2021-07-23 Impact factor: 12.701